BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Royalty Deal May Settle Lawsuit Over InterMune, Inc. (ITMN) Lung Drug


2/20/2013 8:04:30 AM

InterMune Inc. will pay a Japanese drug maker a 4.25 percent royalty on European sales from this year into 2021 of its treatment for a fatal lung-scarring disease, according to a proposed settlement of a lawsuit. Importantly for Brisbane-based InterMune (NASDAQ: ITMN), it will not pay a royalty to Shionogi & Co. of Osaka, Japan, on potential U.S. sales of the drug, known as Esbriet or pirfenidone, unless it uses certain data from Shionogi's studies. InterMune has estimated 2012 European sales of the idiopathic pulmonary fibrosis treatment at $26.1 million. Final sales figures are expected Thursday, when InterMune releases its financial report. Esbriet was rejected in May 2010 by the Food and Drug Administration, but InterMune is undertaking a Phase III trial to win U.S. approval. Shionogi, which won approval of the drug in Japan in 2008 and licensed it to InterMune, brought the suit last summer in U.S. District Court in San Francisco. It claimed that InterMune breached its collaboration deal by submitting proprietary information from Shionogi's clinical trials of pirfenidone in a regulatory filing with the European Medicines Agency.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES